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5-HT1A receptorNMDA receptors have been implicated in the acute response to stress, possibly mediated the nitric oxide path-
way; serotonin has also been implicated in these responses, and has recently been shown to modulate the nitric
oxide pathway via 5-HT1 and 5-HT2 receptors. In this work, we compare the effects of NMDA and a 5-HT1A recep-
tor ligands on light/dark preference in adult zebraﬁsh, and investigate whether nitric oxide mediates the effects
of such drugs. The noncompetitive NMDA receptor antagonist MK-801 decreased dark preference (scototaxis),
while NMDA increased it; the effects of NMDA were completely blocked by pretreatment with the nitric oxide
synthase (NOS) antagonist L-NAME. SNP, a nitric oxide donor, produced a bell-shaped dose–response proﬁle
on scototaxis. Treatment with 5-HTP increased scototaxis, an effect which was potentiated by pre-treatment
withNMDA, but notMK-801, andpartially blockedby L-NAME. The 5-HT1A receptor antagonistWAY100,635 de-
creased scototaxis, an effect which was completely blocked by L-NAME. These results suggest that tonic NOS in-
hibition is an important downstreameffector of 5-HT1A receptors in the regulation of dark preference behavior in
zebraﬁsh, and that NOS is also under phasic independent control by NMDA receptors.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Glutamate has been implicated in the acute response to stress
(Hamane et al., 2009; Harvey, 2006; Lupinsky et al., 2010; Reznikov
et al., 2007) as well as in the expression of defensive behavior
(Yilmazer-Hanke et al., 2003). Glutamate exerts its actions in the central
nervous system throughmetabotropic and ionotropic receptors; among
the latter, the N-methyl-D-aspartate (NMDA) receptor is among the
most studied. The NMDA receptor gates inward sodium and calcium
currents, and the inﬂux of calcium into the cell leads to the activation
of a calcium-dependent isoform of nitric oxide synthase (NOS) and,
consequently to the activation of the nitric oxide–cyclic guanosine
monophosphate (cGMP) pathway (Garthwaite, 2008). Nitric oxide-
producing cells are enriched in regions of the limbic systemwhich orga-
nize defensive behavior in mammals (Matsushita et al., 2001; Simpson
et al., 2003; Vincent and Kimura, 1992; Wang et al., 1995), amphibians
(López et al., 2005) and ﬁsh (Bordieri et al., 2005; Giraldez-Perez et al.,nin; cGMP, cyclic guanosine
itric oxide; NOS, nitric oxide
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).2008; Holmqvist et al., 2007, 2000; Virgili et al., 2001). In rodents,
nitrergic neurons are activated after exposure to anxiogenic contexts
(Beijamini and Guimarães, 2006), restraint stress (De Oliveira et al.,
2000), or ethanol withdrawal (Bonassoli et al., 2011). Systemically,
treatment with NOS inhibitors is anxiolytic in the elevated T-maze
(Calixto et al., 2001), in the staircase test (Pokk and Väli, 2002) and in
the inhibitory avoidance test (Akar et al., 2007).
There are someevidences that the nitrergic system interactswith se-
rotonin (5-HT), an important mediator of defensive behavior across
species (Maximino, 2012). The raphe nuclei, sites of origin of serotoner-
gic innervation in the central nervous system, project nitrergic ﬁbers to
many different sites (Lu et al., 2010; Okere and Waterhouse, 2006;
Simpson et al., 2003;Wang et al., 1995). Microinjection of NO inhibitors
in the raphe blocks the local NMDA-induced 5-HT release (Smith and
Whitton, 2000), prevents the effects of inescapable stress on escape
responding and conditioned fear (i.e., learned helplessness) (Grahn
et al., 2000) and has a biphasic effect in the Porsolt forced swim test
and in the elevated plus-maze (Spiacci Jr et al., 2008). Microinjection
of peroxynitrite donors, on the other hand, increases locomotor activity,
an effect which is blocked by pre-treatment with the 5-HT1A receptor
agonist 8-OH-DPAT (Gualda et al., 2011). The relationship is bilateral,
as the activation of 5-HT1A receptors in neocortex (Maura et al., 2000)
or hippocampal (Strosznajder et al., 1996) slices reduces glutamate-
evoked NO production. In cultured hippocampal neurons, treatment
98 A.M. Herculano et al. / Pharmacology, Biochemistry and Behavior 129 (2015) 97–104with 5-HT or 8-OH-DPAT downregulates NOS protein expression, an
effect which is blocked by treatment with the 5-HT1AR antagonist
NAN-190 (Zhang et al., 2010); in the hippocampus of mice treated
with 8-OH-DPAT for 3 days, NOS-1 mRNA is downregulated, and
NAN-190 increases NOS-1 mRNA by itself (Zhang et al., 2010). Interest-
ingly, in NOS-1 knockout mice, the anxiolytic effect of chronic 8-OH-
DPAT treatment is absent, and pre-treatment with the NOS inhibitor
7-NI blocks the anxiogenic effect of NAN-190 microinjected in the hip-
pocampi of wild-type animals (Zhang et al., 2010).
Zebraﬁsh (Danio rerio Hamilton 1822) have recently been intro-
duced in the ﬁeld of behavioral neuroscience and biological psychiatry
(Gerlai, 2010; Norton and Bally-cuif, 2010), especially in the ﬁeld of
stress and anxiety research (Jesuthasan, 2011; Kalueff et al., 2012;
Maximino et al., 2010b; Steenbergen et al., 2011; Stewart et al., 2011).
The serotonergic system of this teleost is relatively conserved
(Lillesaar, 2011; Maximino et al., 2013a), although some differences
exist such as the duplication genes encoding synthetic enzymes, recep-
tors and transporters (Bellipanni et al., 2002; Norton et al., 2008; Wang
et al., 2006), the existence of a single copy of monoamine oxidase
(Anichtchik et al., 2006), and nuclei outside the raphe (Kaslin and
Panula, 2001). Nonetheless, the pharmacology of the serotonergic
system seems to be rather conserved (Maximino and Herculano,
2010; Stewart et al., 2013). We have previously demonstrated that the
5-HT1A partial agonist buspirone and the antagonist WAY 100,635
have anxiolytic-like effects in the light/dark and in the novel tank tests
(Maximino et al., 2013b, 2011). In this article, we investigate whether
the nitrergic system mediates some of these behavioral effects.
2. Materials and methods
2.1. Animals
247 adult (~4 month) unsexed zebraﬁsh from the striped longﬁn
wild-type phenotype were acquired in a local pet shop and used in the
present experiments. Animals were group-housed in 40 L tanks, with a
maximum density of 25 ﬁsh per tank, for at least 2 weeks before exper-
iments begun. Tanks were ﬁlled with deionized and reconstituted water
at room temperature (28 °C) and a pH of 7.0–8.0. Lighting was provided
byﬂuorescent lamps in a cycle of 14–10h (LD), according to the standard
of care zebraﬁsh (Lawrence, 2007). All manipulations minimized their
potential suffering, as per the recommendations of the Canadian Council
on Animal Care (Canadian Council on Animal Care, 2005). All procedures
complied with the Brazilian Society for Neuroscience and Behavior's
(SBNeC) guidelines for the care and use of animals in research.
2.2. Drugs
All drugs were bought from Sigma-Aldrich (St Louis, MO, USA), dis-
solved in Cortland's salt solution (Wolf, 1963), and injected intraperito-
neally in cold-anesthetized animals (Kinkel et al., 2010). To provide a
picture of the role of NMDA receptors in zebraﬁsh anxiety-like behavior,
NMDA (0 and 0.011 mg/kg; n = 6 per group) and MK-801 (0, 0.2 and
2.0mg/kg; n=10per group)were used to activate and block the recep-
tor, respectively. The role of NOS as a downstreameffector ofNMDAwas
tested by pre-treating animals with the NOS inhibitor L-NAME (0 and
5.0 mg/kg; n = 6 per group) before NMDA injection. The role of
NO was further analyzed by injecting animals with the NO donor
sodium nitroprusside (SNP, 0.5–10 mg/kg; n = 6–7 per group).
Serotonergic tonus was increased by injecting the precursor 5-HTP (0
and 300 mg/kg; n = 9–10 per group); the interaction between 5-HT
and the glutamate–NMDA pathway was analyzed by pre-treating 5-
HTP-injected animals with either NMDA (0 and 0.011 mg/kg; n = 10
per group) or MK-801 (0 and 0.2 mg/kg; n = 10 per group). To analyze
the mediation of NOS in the effects of 5-HTP, animals were pre-treated
with L-NAME (0 and 5.0 mg/kg; n = 9 per group). To understand the
role of 5-HT1A receptors, the antagonist WAY 100,635 (0 and0.03 mg/kg; n = 8–9 per group) was injected; ﬁnally, the mediation of
NOS on the effects ofWAY100,635was analyzed by pre-treating animals
with L-NAME (5.0 mg/kg). With the exception of WAY 100,635 and 5-
HTP, which were tested at these doses in zebraﬁsh (Maximino et al.,
2013b; Herculano andMaximino, 2014), all doses were based on rodent
literature (Olney et al., 1979; Plaznik et al., 1994; Calixto et al., 2001).
2.3. Light/dark preference
The light/dark preference test analyzes zebraﬁsh exploratory behav-
ior under motivational conﬂict, as opposed to escape as has been pro-
posed in the novel tank test (Maximino et al., 2012). In addition, the
effects of serotonergic (Maximino et al., 2013b, 2014) and glutamatergic
agents (Maximino et al., 2014) have been described in this test. Thus,
determination of drug effects on scototaxis was carried as described
elsewhere (Araujo et al., 2012; Maximino et al., 2010a). Brieﬂy,
30min after drug injection animalswere transferred to the central com-
partment of a black and white tank (15 cm × 10 cm × 45 cm h × d × l)
for a 3-min acclimation period, after which the doors which delimit this
compartment were removed and the animal was allowed to freely ex-
plore the apparatus for 15 min. The following variables were manually
recorded by an observer blind to treatment:
time on the white compartment: the time spent in the white portion
of the tank (percentage of the trial);
squares crossed: the number of 10 cm2 squares crossed by the animal
in the white compartment;
latency to white: the amount of time the animal spends in the black
compartment before its ﬁrst entry in the white compartment(s);
entries in white compartment: the number of entries the animal
makes in the white compartment in the whole session;
erratic swimming: the number of “erratic swimming” events, deﬁned
as a zig-zag, fast, and unpredictable course of swimming of short
duration;
freezing: the proportional duration of freezing events (in % of time in
the white compartment), deﬁned as complete cessation of move-
ments with the exception of eye and operculae movements;
thigmotaxis: the proportional duration of thigmotaxis events (in % of
time in thewhite compartment), deﬁned as swimming in a distance
of 2 cm or less from the white compartment's walls; and
risk assessment: the number of “risk assessment” events, deﬁned as a
fast (b1 s) entry in the white compartment followed by re-entry in
the black compartment, or as a partial entry in the white compart-
ment (i.e., the pectoral ﬁn does not cross the midline).
2.4. Statistical analysis
Drug effects on behavioral parameterswere analyzed using one-way
parametric or non-parametric (Kruskal–Wallis) analyses of variance
followed by Tukey's HSD post-hoc tests whenever appropriate. Results
from these statistical analyses were considered signiﬁcant when
p b 0.05. Latency outcomes were analyzed by log-rank Mantel–Cox
tests based on survival curves (Jahn-Eimermacher et al., 2011), with α
for multiple comparisons adjusted by the Bonferroni method.
3. Results
3.1. NMDA ligands alter behavior in the light/dark test in a NOS-dependent
way
Treatmentwith 0.2 mg/kg, but not 2.0mg/kg, MK-801 increased the
time spent on the white compartment (F2, 29 = 11.34, p = 0.0003;
Fig. 1A). The highest dose increased the number of entries in the
white compartment (F2, 29 = 32.82, p b 0.0001; Fig. 1C) and decreased
thigmotaxis (Fig. 1G). No other effects were observed. Treatment
with 0.011 mg/kg NMDA decreased the time spent in the white
Fig. 1. Effects of acute intraperitoneal injection of the NMDA antagonist MK-801 on zebraﬁsh behavior in the light/dark test. (A) Scototaxis; (B) dark preference habituation; (C) entries in
the white compartment; (D) number of squares crossed in the white compartment; (E) erratic swimming; (F) freezing; (G) thigmotaxis; and (H) risk assessment. Bar graphs represent
mean ± standard error, while boxplots represent data from the 25th to the 75th percentile (boxes) and fromminimum to maximum (whiskers). Survival plots represent Kaplan–Meier
estimates for the cumulative incidences of ﬁrst entry latencies. ***, p b 0.001 vs. control; **, p b 0.01 vs. control; *, p b 0.05 vs. control.
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L-NAME in a dose which was by itself ineffective (F3, 23 = 33.13, p b
0.0001; Fig. 2A); moreover, NMDA impaired white avoidancehabituation, an effect which again was blocked by pre-treatment
with L-NAME (F3, 23 = 3.811, p = 0.0261; Fig. 2B). NMDA, L-NAME or
both drugs did not alter the latency to enter the white compartment
Fig. 2. Effects of acute intraperitoneal injection of NMDA and/or L-NAME on zebraﬁsh behavior in the light/dark test. (A) Scototaxis; (B) dark preference habituation; (C) entries in the
white compartment; (D) number of squares crossed in the white compartment; (E) erratic swimming; (F) freezing; (G) thigmotaxis; and (H) risk assessment. Bar graphs represent
mean ± standard error, while boxplots represent data from the 25th to the 75th percentile (boxes) and from minimum to maximum (whiskers). Survival plots represent Kaplan–
Meier estimates for the cumulative incidences of ﬁrst entry latencies. ***, p b 0.001 vs. control; **, p b 0.01 vs. control; *, p b 0.05 vs. control.
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Fig. 4. Effects of 5-HTP, with or without pretreatment with (A) NMDA or MK-801, or
(B) L-NAME on scototaxis in the light/dark test. Different colors represent statistically
signiﬁcant differences.
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served on the number of white compartment entries (H[df = 4] =
2.769, p = 0.4286; Fig. 2C) or on the number of squares crossed in the
white compartment (H[df = 4] = 3.894, p = 0.2732; Fig. 2D). NMDA in-
creased the frequency of erratic swimming events (H[df = 4] = 7.896,
p = 0.0482; Fig. 2E) and risk assessment (H[df = 4] = 11.95, p =
0.0076; Fig. 2H), and the duration of freezing events (F3, 23 = 9.404,
p = 0.0004; Fig. 2F) and thigmotaxis (F3, 23 = 6.5, p = 0.003;
Fig. 2G); in all cases, L-NAME pre-treatment blocked the effects of
NMDA.
3.2. A nitric oxide donor produces biphasic effects on scototaxis
To further understand the role of nitric oxide on the control of
anxiety-like behavior, we administered sodium nitroprusside (SNP), a
nitric oxide donor, in ﬁve doses (from 0.5 to 10 mg/kg) in zebraﬁsh
and recorded their behavior in the light/dark test. SNP increased
the time on white at 1 and 5 mg/kg, and decreased it at 10 m/kg
(F[5, 39] = 30.65, p b 0.0001; Fig. 3A); these effects approached a
bell-shaped curve when log dose–response was analyzed (unweighted
r2 = 0.8526). No effects were observed on the total locomotion in the
dose range analyzed (F[5, 40] = 1.224, p = 0.3188; Fig. 3B).
3.3. Synergism between 5-HTP and NMDA treatments in scototaxis
Treatment with 5-HTP (300mg/kg) decreased time on white, an ef-
fect which was potentiated by pre-treatment with NMDA (F[2, 54] =
15.78, p b 0.0001 for the interaction term; Fig. 4A). Pre-treatment
withMK-801, however, did not alter the effect of 5-HTP on scototaxis—
contrary to what happened with pre-treatment with L-NAME, which
partially blocked the effect of 5-HTP on scototaxis (F[1, 32] = 3.417,
p = 0.05; Fig. 4B). These results suggest that the activation of 5-HT re-
ceptors increases scototaxis, an effect which is potentiated, but notFig. 3. Effects of acute treatment with sodium nitroprusside (SNP) on (A) scototaxis; and
(B) number of midline crossings in the light/dark test. Bar graphs and dot-plots represent
mean ± standard error. ***, p b 0.001 vs. control; **, p b 0.01 vs. control; *, p b 0.05 vs.
control.dependent on, activation of theNMDA receptor;moreover, these effects
are dependent on the activation of nitric oxide synthase.
3.4. Effects of WAY 100,635 mediated by nitric oxide
WAY 100,635 increased the time spent on white, an effect
which was blocked by pre-treatment with L-NAME (F4, 39 = 5.614,
p = 0.0013; Fig. 5A). No effect was observed on latency to white
(χ2[df = 4] = 2.573, p = 0.6317; data not shown), squares crossed
on white (H[df = 5] = 3.23, p = 0.5201; Fig. 5B) or entries on white
(H[df = 5] = 6.661, p = 0.1549; Fig. 5C). While WAY 100,635 by itself
had no effect on thigmotaxis, pre-treatment with L-NAME plus the
highest dose of the 5-HT1AR antagonist decreased it (F4, 39 = 3.093,
p = 0.0279; Fig. 5G). No effect was observed on freezing (F4, 39 =
0.1335, p = 0.969; Fig. 5F) nor on erratic swimming (H[df = 5] =
4.077, p=0.3957; Fig. 5E). The highest dose decreased risk assessment,
an effect whichwas blocked by L-NAME (H[df = 5]= 11.87, p= 0.0183;
Fig. 5H).
4. Discussion
In the present work, NMDA was found to increase scototaxis, im-
paired habituation, and increased erratic swimming, risk assessment,
freezing and thigmotaxis in the light/dark tank — effects which were
blocked by pre-treatment with a NOS antagonist, L-NAME; treatment
with the NMDA non-competitive antagonist MK-801 decreased
scototaxis, but did not alter other variables. Similarly, treatment of
rodents with MK-801 showed an anti-conﬂict effect and reduced thig-
motaxis in an open-ﬁeld (Plaznik et al., 1994), while in the plus-maze
another non-competitive antagonist is ineffective (Wiley et al., 1995).
Fig. 5.Effects ofWAY100,635,with orwithout pretreatmentwith L-NAME, on (A) scototaxis, (B) latency towhite, (C) number of squares crossed in thewhite compartment, (D) entries on
the white compartment, (E) thigmotaxis, (F) freezing, (G) erratic swimming and (H) risk assessment. **, p b 0.01 vs. control (0.0 mg/kg); *, p b 0.05 vs. control.
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(Sison andGerlai, 2011), although the preference task used differed sig-
niﬁcantly from that presented here in that the light side is actually a
transparent, well-lit portion, while the dark side is covered from the
top; in this conﬁguration, animals tend to prefer the light side, instead
of the dark one (Blaser and Peñalosa, 2011; Gerlai et al., 2000), and
thus comparison of these results with ours is limited. In zebraﬁsh,
MK-801 has also been shown to produce hyperactivity (Sison and
Gerlai, 2011) and to block habituation of the acoustic startle response
(Best et al., 2008; Roberts et al., 2011). Other drugs with
antiglutamatergic effects have been shown to affect zebraﬁsh behavior.
Most extensively used were drugs with psychotomimetic effects
(kynurenic acid, ketamine, MK-801, ibogaine; phencyclidine;
Neelkantan et al., 2013) with a polypharmaceutical proﬁle which in-
cludes but is not limited to glutamate. In general, these drugs produce
an anxiolytic-like proﬁle in different tests that is also accompanied by
dissociative-like behavior, suggesting nonspeciﬁc effects on anxiety.
Nonetheless, MK-801 effects on the light/dark test, as well as the
NMDA experiments reported in this paper, suggest that activation of
this receptor increases anxiety-like behavior, an effect mediated by
nitric oxide production.
Previous work showed that freezing and thigmotaxis are higher in
the black compartment of a light/dark tank (Blaser et al., 2010; Blaser
and Peñalosa, 2011), there is no evidence so far that these variables
are increased/decreased by anxiolytic-like and anxiogenic-like treat-
ments. Indeed, Blaser and Peñalosa (2011) did not observe changes in
freezing or thigmotaxis in black after ethanol treatment. On the other
hand, freezing and/or thigmotaxis on white have been repeatedly
shown to be altered by drug treatments (e.g., Maximino et al., 2013b,
2014). The same was observed in the present experiments regarding
the effects of NMDA. While this might represent a methodological lim-
itation of the presentwork, these observations also suggest that freezing
and thigmotaxis in the white compartment are qualitatively different
from these behaviors in the black compartment andmight be controlled
by different behavioral states. Further experiments are necessary to
disentangle this hypothesis.
Nonetheless, stimulation of NO targetswith the donor SNP produced
a biphasic effect on scototaxis— that is, small and intermediate doses in-
crease scototaxis, while intermediate doses decrease it. Biphasic effects
of NO donors were observed on 5-HT release in hypothalamic slices
(Kaehler et al., 1999), and 8-Br-cGMP also affects 5-HT uptake in mid-
brain synaptosomes in a biphasic manner (Ramamoorthy et al., 2007).
Low doses of L-NAME increase open arm exploration in the elevated
plus-maze and decrease immobility in the forced swim test in rats,
while high doses decrease locomotor activity (Spiacci Jr et al., 2008).
These results seem to suggest that themediation of the nitrergic system
on behavior or on the serotonergic system is complex, depending on the
basal and stimulated levels of nitric oxide.
Consistent with these observations, we observed that treatment
with the 5-HT precursor 5-HTP increased scototaxis, an effect which
was potentiated by pre-treatment with NMDA and partially blocked
by pre-treatment with L-NAME. Nonetheless, pre-treatment with MK-
801 was unable to change this effect, suggesting that either activation
of a different site in the NMDA receptor (the orthosteric site) is needed
for synergismwith 5-HTP, or that the effects of 5-HTPweremediated by
nitric oxide downstream of the NMDA receptor. In consonance with this
proposal, in cortical or hippocampal slices, the activation of 5-HT1A re-
ceptors reduces glutamate-evoked NO production (Maura et al., 2000;
Strosznajder et al., 1996).
Previous experiments in zebraﬁsh demonstrated that WAY 100,635
by itself produced an anxiolytic-like effect in both the novel tank and
the light/dark tests (Maximino et al., 2013b). More interestingly, pre-
treatment with L-NAME completely blocked the effects of WAY
100,635 on scototaxis and risk assessment, suggesting that nitric oxide
might be involved in the mechanism of action of this drug. Combined
with the previous observations, these results suggest that 5-HT1Areceptors (blocked by WAY 100,635) tonically inhibit nitric oxide pro-
duction; the removal of this tonic inhibition would increase NO levels
in small increments (as observed in rodent cortical or hippocampal
slices; Maura et al., 2000; Strosznajder et al., 1996), decreasing
scototaxis and risk assessment. NMDA receptor activation, on the
other hand, can directly activate NOS, effectively overriding the tonic in-
hibition and increasing intracellular NO production to levels which in-
crease scototaxis and risk assessment, as well as fear-like behaviors
such as erratic swimming, freezing and thigmotaxis. Therefore, NOS
could act as a “switch” to signal the balance of serotonergic and gluta-
matergic input to post-synaptic structures associated with defensive
behavior.
The present results suggest that tonic NOS-1 inhibition is an impor-
tant downstream effector of 5-HT1A receptors in the regulation of
anxiety-like behavior, and that NOS-1 is also under phasic independent
control by NMDA receptors; however, the precise mechanisms by
which these receptors interact to regulate anxiety-like behavior is still
unclear, and further experiments are necessary to untangle concurrent
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